➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Johnson and Johnson
McKinsey
Boehringer Ingelheim
McKesson
AstraZeneca

Last Updated: June 13, 2021

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 209776


Email this page to a colleague

« Back to Dashboard

NDA 209776 describes VABOMERE, which is a drug marketed by Rempex and is included in one NDA. It is available from one supplier. There are five patents protecting this drug. Additional details are available on the VABOMERE profile page.

The generic ingredient in VABOMERE is meropenem; vaborbactam. There are thirty-two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the meropenem; vaborbactam profile page.
Summary for 209776
Tradename:VABOMERE
Applicant:Rempex
Ingredient:meropenem; vaborbactam
Patents:5
DrugPatentWatch® Estimated Generic Entry Opportunity Date for 209776
Generic Entry Date for 209776*:
Constraining patent/regulatory exclusivity:
Dosage:
POWDER;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NDA: 209776
Mechanism of Actionbeta Lactamase Inhibitors
Suppliers and Packaging for NDA: 209776
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
VABOMERE meropenem; vaborbactam POWDER;INTRAVENOUS 209776 NDA Melinta Therapeutics, LLC 70842-120 70842-120-06 6 VIAL, SINGLE-DOSE in 1 CARTON (70842-120-06) > 2 g in 1 VIAL, SINGLE-DOSE (70842-120-01)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:POWDER;INTRAVENOUSStrength1GM/VIAL;1GM/VIAL
Approval Date:Aug 29, 2017TE:RLD:Yes
Patent:  Get Started FreePatent Expiration:Aug 8, 2031Product Flag?YSubstance Flag?Delist Request?
Patent:  Get Started FreePatent Expiration:Aug 8, 2031Product Flag?Substance Flag?Delist Request?
Patented Use:TREATMENT OF COMPLICATED URINARY TRACT INFECTION (CUTI) INCLUDING PYELONEPHRITIS CAUSED BY THE FOLLOWING SUSCEPTIBLE MICROORGANISMS: ESCHERICHIA COLI, KLEBSIELLA PNEUMONIA, AND ENTEROBACTER CLOACAE SPECIES COMPLEX
Patent:  Get Started FreePatent Expiration:Aug 8, 2031Product Flag?Substance Flag?Delist Request?
Patented Use:TREATMENT OF COMPLICATED URINARY TRACT INFECTION (CUTI) INCLUDING PYELONEPHRITIS CAUSED BY THE FOLLOWING SUSCEPTIBLE MICROORGANISMS: ESCHERICHIA COLI, KLEBSIELLA PNEUMONIA, AND ENTEROBACTER CLOACAE SPECIES COMPLEX

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Baxter
Moodys
Boehringer Ingelheim
Medtronic
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.